USPTO Art Unit 1635 Prosecution Statistics

Art Unit Information

Art Unit: 1635
Group: 1630
Tech Center: 1600
Total Cases: 10,274
Last Active: September 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19323583COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2025October 2025Allow200NoNo
19268623COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSIONJuly 2025January 2026Allow610YesNo
19258035OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSIONJuly 2025December 2025Allow500NoNo
19219917COMPOSITIONS AND METHODS FOR TREATMENT OF KIDNEY DISEASEMay 2025March 2026Allow1020YesNo
19216307COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025January 2026Allow810NoNo
19216250COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025December 2025Allow710NoNo
19216195COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMay 2025January 2026Allow710NoNo
19196434IDENTIFICATION OF MICRORNA BIOMARKERS FOR DIAGNOSIS AND TREATMENT FOR SLEEP APNEAMay 2025October 2025Allow600NoNo
19187919METHOD AND SYSTEM FOR IDENTIFYING SMALL MOLECULE BINDERS WITHIN DNA-ENCODED LIBRARY DATASETApril 2025November 2025Allow610YesNo
19092326COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMarch 2025October 2025Allow610NoNo
19092703COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDMarch 2025December 2025Allow910NoNo
19077324MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYMarch 2025August 2025Allow510NoNo
19054630COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONFebruary 2025April 2025Allow200YesNo
19027181Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsJanuary 2025November 2025Allow1010YesNo
19023934Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsJanuary 2025March 2026Allow1410YesNo
19011407Novel CRISPR-Cas sigma enzyme and systemJanuary 2025January 2026Allow1230NoNo
19007236COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSIONDecember 2024March 2025Allow300YesNo
19002832Compositions for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsDecember 2024October 2025Allow1010YesNo
18982078Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellDecember 2024September 2025Allow911NoNo
18979415COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1120NoNo
18979378COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1220NoNo
18977470COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18977518COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18977579COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18976043COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1310YesNo
18976118COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18976156COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024October 2025Allow1110NoNo
18971273COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1310NoNo
18970575BASE EDITOR AND THE USE THEREOFDecember 2024December 2025Allow1220YesNo
18970549COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18970618COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024January 2026Allow1410NoNo
18970559COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18969803COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18970411COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18969769COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1210NoNo
18968602COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1220NoNo
18968659COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024December 2025Allow1220NoNo
18968895COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1110NoNo
18968892COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDDecember 2024November 2025Allow1210NoNo
18957819TRANSCRIPTION FACTOR NCGL0581 MUTANT AND USE THEREOF IN L-SERINE DETECTIONNovember 2024July 2025Allow720YesNo
18932745COMPOSITIONS FOR INDUCING MODIFICATIONS OF TARGET ENDOGENOUS NUCLEIC ACID SEQUENCES IN NUCLEUSES OF EUKARYOTIC CELLSOctober 2024August 2025Allow1020YesNo
18933878COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520NoNo
18932078COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520YesNo
18932316COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18932213COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1320NoNo
18932216COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1420YesNo
18932368COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024December 2025Allow1420YesNo
18931873COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024November 2025Allow1220NoNo
18932265COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024October 2025Allow1220NoNo
18931989COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024April 2025Allow520NoNo
18932105COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDOctober 2024January 2026Allow1420YesNo
18928880CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOFOctober 2024May 2025Allow610YesNo
18920273THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERSOctober 2024October 2025Allow1230YesNo
18915035EFFICIENT SYNTHESIS AND ASSEMBLY METHOD FOR LARGE FRAGMENT DNA BASED ON PROGRAMMABLE NUCLEASE ARGONAUTEOctober 2024April 2025Allow610NoNo
18898720NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TRANSFERRIN RECEPTOR 2September 2024September 2025Allow1121YesNo
18887946COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACIDSeptember 2024March 2025Allow620NoNo
18886396APOPTOTIC CELL MIMICSeptember 2024April 2025Allow710YesNo
18820460CRISPR-CAS SYSTEMS AND USES THEREOFAugust 2024July 2025Allow1120YesNo
18819737RNAi Agents for Inhibiting Expression of Inhibin Subunit Beta E (INHBE), Pharmaceutical Compositions Thereof, and Methods of UseAugust 2024March 2025Allow610YesNo
18819435MODELS OF TAUOPATHYAugust 2024April 2025Allow810NoNo
18799447MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHYAugust 2024December 2024Allow410NoNo
18797746BIOMARKER FOR PREDICTING DRUG RESISTANCE OF BRUTON'S TYROSINE KINASE INHIBITORS AND APPLICATION THEREOFAugust 2024January 2025Allow510NoNo
18794874Enzymatic RNA Capping MethodAugust 2024October 2025Allow1541NoNo
18791380ADVANCED RNA TARGETING (ARNATAR)July 2024January 2026Abandon1821YesNo
18781640RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USEJuly 2024July 2025Allow1211NoNo
18777266COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJuly 2024January 2026Abandon1830NoNo
18774194Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameJuly 2024January 2026Allow1811NoNo
18768373OLIGONUCLEOTIDES COMPRISING SEGMENTED GAP STRUCTURESJuly 2024January 2026Allow1831YesNo
18765750SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJuly 2024February 2025Allow710NoNo
18765286RESTORATION OF THE CFTR FUNCTION BY SPLICING MODULATIONJuly 2024April 2025Allow920YesNo
18755750CRISPR-CAS13 SYSTEM AND USE THEREOFJune 2024January 2025Allow710YesNo
18741110ANTISENSE OLIGONUCLEOTIDE TARGETING ATN1 MRNA OR PRE-MRNAJune 2024December 2024Allow710YesNo
18739091COMPOSITION FOR REGULATING PRODUCTION OF PROTEINSJune 2024January 2025Allow710YesNo
18738165STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJune 2024November 2025Allow1701NoNo
18715637RECOMBINANT COLLAGEN AND PREPARATION METHOD AND USE THEREOFMay 2024May 2025Allow1210YesNo
18673713TRANS-SPLICING MOLECULESMay 2024June 2025Allow1300NoNo
18662046Antisense Nucleic AcidsMay 2024October 2025Abandon1720NoNo
18661339METHODS OF TREATING OR PREVENTING SPINAL MUSCULAR ATROPHYMay 2024October 2024Abandon510NoNo
18660713HYPOIMMUNOGENIC CELL AND METHODS OF GENERATION THEREOFMay 2024September 2025Abandon1620NoNo
18655096SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESMay 2024October 2025Allow1710NoNo
18646631APTAMERS FOR BINDING TO A MEMBRANE-BASED LIPIDApril 2024December 2024Allow811NoNo
18643870DIGITAL COUNTING OF INDIVIDUAL MOLECULES BY STOCHASTIC ATTACHMENT OF DIVERSE LABELSApril 2024November 2025Allow1810YesNo
18634158USE OF PI3KC2B INHIBITORS FOR THE PRESERVATION OF VASCULAR ENDOTHELIAL CELL BARRIER INTEGRITYApril 2024September 2025Abandon1701NoNo
18633108HIPPO AND DYSTROPHIN COMPLEX SIGNALING IN CARDIOMYOCYTE RENEWALApril 2024August 2025Allow1610NoNo
18630828COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICSApril 2024January 2025Allow1021YesNo
18625829TREATMENT OF MST1 RELATED DISEASES AND DISORDERSApril 2024August 2024Abandon401YesNo
18623472STAUFEN1 REGULATING AGENTS AND ASSOCIATED METHODSApril 2024October 2025Allow1920NoNo
18620640A METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKSMarch 2024July 2025Allow1521NoNo
18620644METHOD FOR THE ISOLATION OF DOUBLE-STRAND BREAKSMarch 2024July 2025Allow1520NoNo
18617486SYSTEMS AND METHODS FOR ASSOCIATING COMPOUNDS WITH PROPERTIES USING CLIQUE ANALYSIS OF CELL-BASED DATAMarch 2024March 2025Allow1220NoNo
18610930RNAi Agents for Inhibiting Expression of Complement Factor B (CFB), Pharmaceutical Compositions Thereof, and Methods of UseMarch 2024March 2025Allow1221NoNo
18608025APOPTOTIC CELL MIMICMarch 2024August 2024Allow511YesNo
18608561METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPYMarch 2024September 2025Allow1811NoNo
18606312CONTROL OF INSECT INFESTATIONMarch 2024September 2025Allow1810NoNo
18607210GUIDED MICROBIAL REMODELING, A PLATFORM FOR THE RATIONAL IMPROVEMENT OF MICROBIAL SPECIES FOR AGRICULTUREMarch 2024November 2025Allow2011YesNo
18606473MRNA TREATMENT NANOPARTICLESMarch 2024September 2024Allow620NoNo
18599942METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSIONMarch 2024September 2025Allow1820YesNo
18600486DEEP GENERATIVE MODELS FOR INVERSE DESIGN OF INORGANIC ATOMISTIC STRUCTURESMarch 2024July 2025Abandon1611NoNo
18598943SIRNA STRUCTURES FOR HIGH ACTIVITY AND REDUCED OFF TARGETMarch 2024February 2026Abandon2420NoNo
18592300METHOD AND APPARATUS FOR REDUCING CHEMICAL REACTION MECHANISMSFebruary 2024January 2026Abandon2220YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1635.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
95
Examiner Affirmed
75
(78.9%)
Examiner Reversed
20
(21.1%)
Reversal Percentile
5.6%
Lower than average

What This Means

With a 21.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
874
Allowed After Appeal Filing
118
(13.5%)
Not Allowed After Appeal Filing
756
(86.5%)
Filing Benefit Percentile
1.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1635 - Prosecution Statistics Summary

Executive Summary

Art Unit 1635 is part of Group 1630 in Technology Center 1600. This art unit has examined 10,274 patent applications in our dataset, with an overall allowance rate of 47.6%. Applications typically reach final disposition in approximately 32 months.

Comparative Analysis

Art Unit 1635's allowance rate of 47.6% places it in the 6% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1635 receive an average of 1.78 office actions before reaching final disposition (in the 40% percentile). The median prosecution time is 32 months (in the 40% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.